ArticleJournal of chemical information and modeling2026
Binding of Anthracyclines Within DNA-Topoisomerase ΙΙ Cleavage Complexes: Thermodynamics and Interactions.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
All-atom molecular dynamics simulations of anthracycline-DNA-topoisomerase II (TOPII) cleavage complexes are undertaken in an aqueous environment, with particular emphasis on their thermodynamic description, using the double-decoupling method. Both the TOPIIα and TOPIIβ isoforms are considered herein, with doxorubicin and berubicin, two TOPII poisons, as the anthracyclines of interest. From a thermodynamic point of view, we find that all complexes investigated exhibit more negative standard binding Gibbs energies than berubicin-DNA intercalation complexes, showing that the presence of TOPIIα or TOPIIβ further stabilizes the complexes. The berubicin-DNA-TOPIIα complex exhibits the most negative standard binding Gibbs energy. Therefore, berubicin shows a preference for TOPIIα over TOPIIβ; the former is highly expressed in proliferating cells, including cancer cells, whereas the latter is expressed ubiquitously. From a nanoscopic point of view, our rigorous in silico approach sheds light on the interactions of the two anthracyclines with both DNA and TOPII and on how they contribute to the hindering of religation. Moreover, this study provides a detailed comparison between doxorubicin and berubicin in terms of relevant properties, such as contact numbers, hydrogen bonds, selected distances, and solvent-accessible surface areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.